Finoriq research workspace
Q32 Bio Inc. (QTTB) Historical Metrics
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy. Review QTTB valuation ratios, fundamentals, and filing metrics on Finoriq.
Company Snapshot
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.
- Company
- Q32 Bio Inc. (QTTB)
- Ticker
- QTTB
- Market Cap
- $253.5M
- Latest Price
- $14.95
- Industry
- Biotech & Pharma
Q32 Bio Inc. (QTTB) Current Valuation Metrics
Static valuation preview for Q32 Bio Inc. (QTTB). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/EMarket cap divided by latest TTM net income. | 6.38x | Net Income | TTM Q1 2026 |
| P/SMarket cap divided by latest TTM revenue. | 3.94x | Revenue | TTM FY 2025 |
| Earnings YieldLatest TTM net income divided by market cap. | 15.7% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -12.9% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 4.58x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.